(Q36632665)

15 August 2017

1 reference

title

Pharmacotherapy of Zollinger-Ellison syndrome (English)

1 reference

15 August 2017

0 references

Tetsuhide Ito

1

1 reference

15 August 2017

Hisato Igarashi

series ordinal

2

1 reference

15 August 2017

Hirotsugu Uehara

series ordinal

3

1 reference

15 August 2017

Robert T Jensen

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

30 January 2013

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

14

1 reference

15 August 2017

3

1 reference

15 August 2017

307-321

1 reference

Diagnosis of Zollinger-Ellison syndrome: increasingly difficult

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Everolimus for the treatment of pancreatic neuroendocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Antitumor effects of somatostatin analogs in neuroendocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Molecular pathology and genetics of pancreatic endocrine tumours.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Therapy innovation for the treatment of pancreatic neuroendocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Advances in medical therapies for Cushing's syndrome.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Prescribing proton pump inhibitors: is it time to pause and rethink?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Management of pancreatic neuroendocrine tumors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Radioembolization in the treatment of neuroendocrine tumor metastases to the liver.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

New therapeutic options for metastatic malignant insulinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Targeted therapy in advanced well-differentiated neuroendocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Everolimus for advanced pancreatic neuroendocrine tumors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

State of the art: radiolabeled microspheres treatment for liver malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Long-term survival in a patient with carcinoid syndrome receiving treatment for Zollinger-Ellison syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Gastric acid hypersecretory states: recent insights and advances

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

The safety of H(2)-blockers use during pregnancy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Esomeprazole: a proton pump inhibitor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Control of gastric acid secretion in health and disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Medical treatment of gastrinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Neuroendocrine tumors. Biotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Imaging of neuroendocrine tumours (CT/MR/US).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Gastrinoma (duodenal and pancreatic).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Long-term proton pump inhibitor therapy and risk of hip fracture

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Adrenocorticotropic hormone--secreting islet cell tumors: are they always malignant?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Use of omeprazole in patients with Zollinger-Ellison syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal o

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Prospective study of chemotherapy in patients with metastatic gastrinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Prospective study of the standard meal provocative test in Zollinger-Ellison syndrome.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Gastrinomas: localization by means of selective intraarterial injection of secretin

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Multiple hormone elevations in Zollinger-Ellison syndrome. Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Location, incidence, and malignant potential of duodenal gastrinomas

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome

28 June 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Meningiomas may be a component tumor of multiple endocrine neoplasia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Comparison of Ranitidine and Cimetidine in the Treatment of Gastric Hypersecretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Plasma gastrin measurement cannot be used to diagnose a gastrinoma in patients on either proton pump inhibitors or histamine type-2 receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Biliary stricture: is dilatation an acceptable alternative to operation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Management of the Zollinger-Ellison syndrome in pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

The safety of fetal exposure to proton-pump inhibitors during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Pancreatic neuroendocrine cell tumor secreting parathyroid hormone-related protein and gastrin: Report of a case.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Is total gastrectomy still a viable option in the management of patients with the Zollinger-Ellison syndrome?

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3580316

Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas

20 September 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.767332

Transarterial liver-directed therapies of neuroendocrine hepatic metastases

21 January 2018

1 reference

12 December 2020

Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion

1 reference

12 December 2020

Selective venous sampling for gastrin to localize gastrinomas. A prospective assessment

1 reference

12 December 2020

Cushing's syndrome in patients with the Zollinger-Ellison syndrome

1 reference

12 December 2020

Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome

1 reference

12 December 2020

Zollinger-Ellison syndrome. Clinical presentation in 261 patients

1 reference

12 December 2020

Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery

1 reference

12 December 2020

Promising advances in the treatment of malignant pancreatic endocrine tumors

1 reference

12 December 2020

Surgery increases survival in patients with gastrinoma

1 reference

12 December 2020

Treatment strategies for Zollinger-Ellison syndrome

1 reference

12 December 2020

The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome

1 reference

12 December 2020

Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy

1 reference

12 December 2020

Successful pregnancy in association with Zollinger-Ellison syndrome

1 reference

12 December 2020

Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management

1 reference

12 December 2020

Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study

1 reference

12 December 2020

Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy

1 reference

12 December 2020

A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger-Ellison Syndrome

1 reference

12 December 2020

Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1

1 reference

12 December 2020

Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors

1 reference

12 December 2020

Gastrinomas: comparison of MR imaging with CT, angiography, and US

1 reference

12 December 2020

Neuroendocrine tumors

1 reference

12 December 2020

Metastatic gastrinomas: localization with selective arterial injection of secretin

1 reference

12 December 2020

Reflux esophagitis in patients with Zollinger-Ellison syndrome

1 reference

12 December 2020

Diagnosis of the Zollinger–Ellison syndrome

1 reference

12 December 2020

Neuroendocrine tumors of the pancreas

1 reference

12 December 2020

A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans

1 reference

12 December 2020

The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment

1 reference

12 December 2020

Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1

1 reference

12 December 2020

Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography, and venous sampling

1 reference

12 December 2020

Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high

1 reference

12 December 2020

Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome

1 reference

12 December 2020

Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study

1 reference

12 December 2020

10.1517/14656566.2013.767332

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

23363383

1 reference